Photodynamic therapy with two third dose verteporfin for central serous chorioretinopathy:Prospective intervention trial

Photodynamic therapy with two third dose verteporfin for central serous chorioretinopathy:Prospective intervention trial - Photodynamic therapy with two third dose verteporfin for central serous chorioretinopathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002770

Enrollment

Registered

2009-11-17

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central serous chorioretinopathy

Interventions

4mg/m2 intravenous infusion of verteporfin over 10 minutes followed by delivery of laser at 15 minutes. Nonthermal laser light of 689nm wavelength is applied for 83 sec delivering a dose of 50J/cm2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 3 months or more after onset 2. presence of active angiographic leakage under or adjacent to fovea in fluorescein angiography 3. presence of serous retinal detachment(SRD) on optical coherence tomography(OCT) 4. written informed consent 5. re-treatment is considered to the patients with recurrent or persistent SRD on OCT

Exclusion criteria

Exclusion criteria: 1. drug allery to verteporfin 2. pregnant or expecting pregnancy 3. porphyria, or hypersensitivity to artificial illumination 4. macular diseases other than CSC 5. others (inappropriate case judged by investigator or subinvestigators)

Design outcomes

Primary

Measure	Time frame
resolution of serous retinal detachment of 4 days, 1 month, 3 months, 6 months, and 1 year after PDT	—

Secondary

Measure	Time frame
1)visual acuity 2)thickness of retina and serous retinal detachment at fovea on optical coherence tomography 3)choroidal thickness on optical coherence tomography 4)amplitudes and implicit time of a-wave, b-wave and odcillatory potentials recorded by focal macula electroretinogram 5)visual field 6)fluorescein angiography 7)indocyanine green angiography time of assessment 1)-5) : 4 days, 1 month, 3 months, 6 months, and 1 year after PDT 6),7) : 1 month, 3 months, and 1 year after PDT	—

Measure

Time frame

1)visual acuity 2)thickness of retina and serous retinal detachment at fovea on optical coherence tomography 3)choroidal thickness on optical coherence tomography 4)amplitudes and implicit time of a-wave, b-wave and odcillatory potentials recorded by focal macula electroretinogram 5)visual field 6)fluorescein angiography 7)indocyanine green angiography time of assessment 1)-5) : 4 days, 1 month, 3 months, 6 months, and 1 year after PDT 6),7) : 1 month, 3 months, and 1 year after PDT

—

Countries

Japan

Contacts

Public ContactRuka Maruko

Nagoya University School of Medicine Department of Ophthalmology

rutia@xg8.so-net.ne.jp052-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026